Vonvendi® [von Willebrand factor (recombinant)] – Expanded indication
April 17, 2018 - Shire announced the FDA approval of Vonvendi [von Willebrand factor (recombinant)] for perioperative management of bleeding in adults (age 18 and older) diagnosed with von Willebrand disease (VWD).
Download PDF
